{"id":1011281,"date":"2026-10-19T09:30:37","date_gmt":"2026-10-19T13:30:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/"},"modified":"2026-10-19T09:30:37","modified_gmt":"2026-10-19T13:30:37","slug":"oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/","title":{"rendered":"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026"},"content":{"rendered":"
\n

\n Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET<\/em>\n <\/p>\n

\n Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced a conference call and webcast to review clinical data from the ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations in conjunction with the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.<\/p>\n

The conference call and webcast will take place on Friday, October 23, 2026, at 8:00 am ET. ORIC leadership plans to have Dr. Joshua Sabari, Assistant Professor of Medicine at NYU Grossman School of Medicine, join the call to share his perspective on the enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations. To join the conference call via phone and participate in the live Q&A session, please pre-register online here<\/a> to receive a telephone number and unique passcode required to enter the call. The live webcast and an audio archive of the conference call will be available through the investor section of ORIC\u2019s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.<\/p>\n

Full abstracts of the three poster presentations are available for public viewing via the ESMO Congress website, here<\/a>. Posters will be available for public viewing via the ESMO Congress website on October 23, 2026.<\/p>\n

\n
\n Poster presentation details:<\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Title:<\/strong>\n <\/td>\nEnozertinib (ORIC-114), a Brain Penetrant, Highly Selective<\/td>\n<\/tr>\n
\u00a0<\/td>\nEGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n2627P<\/td>\n<\/tr>\n
\n Session Date & Time:<\/strong>\n <\/td>\nMonday, October 26, 2026; 12:00 \u2013 12:45 p.m. CET<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\n <\/td>\nMetastatic NSCLC<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nRinzimetostat, an Allosteric PRC2 Inhibitor Combined With
Darolutamide: A Global Phase 3 Study in mCRPC Patients
Previously Treated With Abiraterone Acetate (Himalayas-1)<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n2303TiP<\/td>\n<\/tr>\n
\n Session Date & Time:<\/strong>\n <\/td>\nFriday, October 23, 2026; 3:15 \u2013 4:00 p.m. CEST<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\n <\/td>\nMetastatic Prostate Cancer<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\nRinzimetostat, a Next-Generation PRC2 Inhibitor, Enhances
Luminal Fate and AR Signaling While Restricting Lineage
Plasticity in Preclinical Models and Demonstrates Mechanistic Proof-of-Concept in Samples From Patients with mCRPC\u00a0<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n1128eP<\/td>\n<\/tr>\n
\n Session Title:<\/strong>\n <\/td>\nDevelopmental Therapeutics<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About ORIC Pharmaceuticals, Inc.\u00a0<\/strong>
\n
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients\u2019 lives by Overcoming Resistance In Cancer<\/em>. ORIC\u2019s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to\u00a0www.oricpharma.com<\/u><\/a>, and follow us on\u00a0X<\/u><\/a>\u00a0or\u00a0LinkedIn<\/u><\/a>.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com<\/u><\/a>
info@oricpharma.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced a conference call and webcast to review clinical data from the ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations in conjunction with the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, … <\/p>\n

Continue reading “ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011281","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced a conference call and webcast to review clinical data from the ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations in conjunction with the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, … Continue reading "ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-19T13:30:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026\",\"datePublished\":\"2026-10-19T13:30:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/\"},\"wordCount\":508,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/\",\"name\":\"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=\",\"datePublished\":\"2026-10-19T13:30:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 - Market Newsdesk","og_description":"Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced a conference call and webcast to review clinical data from the ongoing Phase 1b trial of enozertinib in first-line NSCLC patients with EGFR atypical mutations in conjunction with the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, … Continue reading \"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-19T13:30:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026","datePublished":"2026-10-19T13:30:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/"},"wordCount":508,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/","name":"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=","datePublished":"2026-10-19T13:30:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzczOCM3OTAxMjY3IzIwODA4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oric-pharmaceuticals-to-host-conference-call-webcast-to-review-enozertinib-data-being-presented-at-esmo-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ORIC\u00ae Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011281"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011281\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}